Building on biomedical research programs, such as the Human Genome Project, and subsequent genomics research and development, PHIX GENOMICS will apply state-of-the-art genomics, bioinformatics and digital imaging technologies to generate the highest resolution, and most comprehensive diagnostic reporting. Using this information, the company will empower healthcare professionals to accurately diagnose and treat disease, anticipate and stop disease, and guide safer therapeutic approaches. Through the application of these disruptive genomic technologies, the foundation for individualized precision medical treatment and personal health care is being layed. By representing the heart of a new paradigm of medicine that is evidence-based and rooted in quantitative science, PHIX Genomics contributes to the improvement of the quality of life for everyone in the Philippines (and beyond).
On the local front, PHIX GENOMICS will establish symbiotic relationships with key public institutions such as the Department of Science and Technology, Department of Health, National Institute of Health, Philippine Genome Center, World Health Organization, etc. Likewise, partnerships with academic and research institutions, as well as key medical institutions and medical associations will be cultivated and maintained. These networking activities will prove most useful as we proceed to develop our physician and consumer markets.
PHIX GENOMICS is founded and led by Mr. Jeffrey Seitz, currently Vice President of D-MARK Biosciences, Canada’s premier provider of advanced solutions for genomics and molecular biology. For the research and phase 1 development, he has formed a team with specialists in their respective fields